Form 8-K

8-K — SUPERNUS PHARMACEUTICALS, INC.

Accession: 0001104659-26-089524

Filed: 2026-08-03

Period: 2026-08-03

CIK: 0001356576

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2622009d4_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622009d4_ex99-1.htm)

GRAPHIC (tm2622009d4_ex99-1img0001.jpg)

GRAPHIC (tm2622009d4_ex99-1img001.jpg)

GRAPHIC (tm2622009d4_ex99-1img002.jpg)

GRAPHIC (tm2622009d4_ex99-1img003.jpg)

GRAPHIC (tm2622009d4_ex99-1img004.jpg)

GRAPHIC (tm2622009d4_ex99-1img005.jpg)

GRAPHIC (tm2622009d4_ex99-1img006.jpg)

GRAPHIC (tm2622009d4_ex99-1img007.jpg)

GRAPHIC (tm2622009d4_ex99-1img008.jpg)

GRAPHIC (tm2622009d4_ex99-1img009.jpg)

GRAPHIC (tm2622009d4_ex99-1img010.jpg)

GRAPHIC (tm2622009d4_ex99-1img011.jpg)

GRAPHIC (tm2622009d4_ex99-1img012.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622009d4_8k.htm · Sequence: 1

false

0001356576

2026-08-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13

or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of

earliest event reported): August 3, 2026

Supernus

Pharmaceuticals, Inc.

(Exact name of registrant

as specified in its charter)

Delaware

001-35518

20-2590184

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S.

Employer Identification No.)

9715

Key West Ave

Rockville

20850

(Address

of Principal Executive Offices)

(Zip

Code)

Registrant’s telephone

number, including area code: (301) 838-2500

Not Applicable

(Former name or former address,

if changed since last report.)

Securities registered pursuant to Section 12(b)

of the Exchange Act

Title of

each class

Trading Symbol

Name of each

exchange on which registered

Common

Stock, $0.001 par value per share

SUPN

The Nasdaq

Stock Market LLC

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

x Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

x Soliciting material pursuant to Rule 14a-12 under the Exchange Act

(17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Indicate by

check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

As previously announced, on August 3, 2026, Supernus

Pharmaceuticals, Inc. (the “Company”) and Indivior Pharmaceuticals Inc. (“Indivior”) are hosting a conference

call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger of the Company and Indivior. The Company

intends to display the slides filed as Exhibit 99.1 hereto during the presentation.

Important Additional Information and Where

to Find It

In connection with the proposed transaction,

Indivior intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus

of Indivior and a joint proxy statement of Indivior and Supernus (the “joint proxy statement/prospectus”). Each party also

plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ

THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN

IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A definitive joint proxy statement/prospectus will be sent to Indivior’s

stockholders and Supernus’ stockholders. Investors and securityholders may obtain a free copy of the joint proxy statement/prospectus

(if and when it becomes available) and other relevant documents filed by Indivior and Supernus with the SEC at the SEC’s website

at www.sec.gov. Copies of the documents filed by Indivior with the SEC will be available free of charge on Indivior’s website

at www.indivior.com or by contacting Indivior’s Investor Relations at InvestorRelations@indivior.com. Copies of the

documents filed by Supernus with the SEC will be available free of charge on Supernus’ website at www.supernus.com.

No Offer or Solicitation

This report and the information contained herein

is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities,

or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation

or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This report does

not constitute a prospectus or prospectus equivalent document. No offer of securities shall be made except by means of a prospectus meeting

the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Indivior and Supernus and their respective directors,

executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect

of the proposed transaction. Information about directors and executive officers of Indivior is available in the Indivior proxy statement

for its 2026 Annual Meeting, which was filed with the SEC on March 27, 2026. Information about directors and executive officers of Supernus

is available in the Supernus proxy statement for its 2026 Annual Meeting, which was filed with the SEC on April 30, 2026. Other information

regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or

otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed

transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available

before making any voting or investment decisions. Investors may obtain free copies of these documents from Indivior and Supernus as indicated

above.

Forward-Looking Statements

This report contains forward-looking statements within the meaning

of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. From time to time, oral or written forward-looking

statements may also be included in other information released to the public. These forward-looking statements are intended to provide

Supernus’s and Indivior’s respective management’s current expectations or plans for our future operating and financial

performance, based on assumptions currently believed to be valid. Words such as “anticipate,” “believe,” “estimate,”

“expect,” “intend,” “plan,” “project,” “may,” “will,” “would,”

“could,” “should,” and similar expressions are intended to identify forward-looking statements, although not all

forward-looking statements contain these words. All forward-looking statements involve risks, uncertainties and other factors that may

cause actual results to differ materially from those expressed or implied in the forward-looking statements. These statements, including

statements regarding the proposed merger of equals of Supernus and Indivior, the expected timing of the closing, and the anticipated benefits

and prospects of the combined company, are based on management’s current expectations and are subject to risks and uncertainties

that could cause actual results to differ materially, including, among others: the risk that the proposed merger may not be completed

in a timely manner or at all; the failure to obtain the required approvals of Supernus' or Indivior’s stockholders; the failure

or delay in obtaining required regulatory approvals, or the imposition of conditions in connection therewith; the failure to satisfy the

other conditions to closing; the possibility that a competing or superior acquisition proposal is made; the fact that the exchange ratio

is fixed and will not be adjusted for changes in the market price of Supernus or Indivior shares; the effect of the announcement, pendency

or completion of the transaction on the market price of Supernus and Indivior shares; the effect of the additional indebtedness incurred

to fund the Special Dividend on the combined company; the effects of business disruption resulting from the announcement or pendency of

the transaction; the diversion of management’s attention and resources from ongoing business operations; the effect of the transaction

on the parties’ ability to retain and hire key personnel and to maintain relationships with customers, suppliers and other business

partners; restrictions during the pendency of the transaction that may limit the parties’ ability to pursue business opportunities

or strategic transactions; the risk that the anticipated benefits, synergies and cost savings may not be realized within the expected

timeframe or at all; the difficulties and costs of integrating the two businesses; significant transaction costs and/or unknown or inestimable

liabilities; the risk that the merger does not qualify for its intended treatment as a tax-free reorganization; the occurrence of any

event that could give rise to termination of the merger agreement, including in circumstances requiring payment of a termination fee;

the risk of stockholder litigation in connection with the transaction; the impact of macroeconomic and market conditions, including economic

downturns, international conflict, trade disputes and tariffs; and the other risks identified in Supernus' and Indivior’s filings

with the SEC and in the joint proxy statement/prospectus when it becomes available. There can be no assurance that the proposed merger

will in fact be consummated in the manner described or at all. These forward-looking statements speak only as of the date of this report

and neither Supernus nor Indivior undertakes any obligation to update any forward-looking statement, except as required by applicable

law.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

Exhibit 99.1 - Investor Presentation, dated August 3, 2026.

Exhibit 104 - The cover page from

this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

SUPERNUS PHARMACEUTICALS, INC.

DATED: August 3, 2026

By:

/s/ Timothy C. Dec

Timothy C. Dec

Senior Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622009d4_ex99-1.htm · Sequence: 2

Exhibit 99.1

Filed by: Supernus Pharmaceuticals, Inc.

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

under the Securities Exchange Act of 1934

Subject Company: Supernus Pharmaceuticals, Inc.

Commission File No.: 001-35518

Date: August 3, 2026

Merger of Equals to Create a

Diversified CNS

Biopharmaceutical Leader

with Significant Scale

AUGUST 3, 2026

Forward Looking Statements

This presentation, and any related oral statements made by representatives of Supernus or Indivior in connection with it, contain forward-looking statements within the meaning of

the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. From time to time, oral or written forward-looking statements may also be included in

other information released to the public. These forward-looking statements are intended to provide Supernus’s and Indivior’s respective management’s current expectations or

plans for our future operating and financial performance, based on assumptions currently believed to be valid. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,”

“plan,” “project,” “may,” “will,” “would,” “could,” “should,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements

contain these words. All forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied

in the forward-looking statements. These statements, including statements regarding the proposed merger of equals of Supernus and Indivior, the expected timing of the closing,

and the anticipated benefits and prospects of the combined company, are based on management’s current expectations and are subject to risks and uncertainties that could cause

actual results to differ materially, including, among others: the risk that the proposed merger may not be completed in a timely manner or at all; the failure to obtain the required

approvals of Supernus' or Indivior’s stockholders; the failure or delay in obtaining required regulatory approvals, or the imposition of conditions in connection therewith; the failure

to satisfy the other conditions to closing; the possibility that a competing or superior acquisition proposal is made; the fact that the exchange ratio is fixed and will not be adjusted

for changes in the market price of Supernus or Indivior shares; the effect of the announcement, pendency or completion of the transaction on the market price of Supernus and

Indivior shares; the effect of the additional indebtedness incurred to fund the Special Dividend on the combined company; the effects of business disruption resulting from the

announcement or pendency of the transaction; the diversion of management’s attention and resources from ongoing business operations; the effect of the transaction on the

parties’ ability to retain and hire key personnel and to maintain relationships with customers, suppliers and other business partners; restrictions during the pendency of the

transaction that may limit the parties’ ability to pursue business opportunities or strategic transactions; the risk that the anticipated benefits, synergies and cost savings may not be

realized within the expected timeframe or at all; the difficulties and costs of integrating the two businesses; significant transaction costs and/or unknown or inestimable liabilities;

the risk that the merger does not qualify for its intended treatment as a tax-free reorganization; the occurrence of any event that could give rise to termination of the merger

agreement, including in circumstances requiring payment of a termination fee; the risk of stockholder litigation in connection with the transaction; the impact of macroeconomic

and market conditions, including economic downturns, international conflict, trade disputes and tariffs; and the other risks identified in Supernus' and Indivior’s filings with the SEC

and in the joint proxy statement/prospectus when it becomes available. There can be no assurance that the proposed merger will in fact be consummated in the manner described

or at all. These forward-looking statements speak only as of the date of this presentation and neither Supernus nor Indivior undertakes any obligation to update any forward-looking statement, except as required by applicable law. This presentation also contains non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA margin and cost

synergies, which are not calculated in accordance with GAAP, should be considered in addition to and not as substitutes for the most directly comparable GAAP measures, and may

not be comparable to similarly titled measures used by other companies.

Additional Information

NO OFFER OR SOLICITATION

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities, or a solicitation of any vote or approval, nor shall

there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This

communication does not constitute a prospectus or prospectus equivalent document. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the

Securities Act of 1933, as amended.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

In connection with the proposed transaction, Indivior intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Indivior and a joint proxy statement of Indivior and

Supernus (the “joint proxy statement/prospectus”). Each party also plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT

PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A

definitive joint proxy statement/prospectus will be sent to Indivior’s stockholders and Supernus’ stockholders. Investors and securityholders may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes

available) and other relevant documents filed by Indivior and Supernus with the SEC at the SEC’s website at www.sec.gov. Copies of the documents filed by Indivior with the SEC will be available free of charge on Indivior’s website at

www.indivior.com or by contacting Indivior’s Investor Relations at InvestorRelations@indivior.com. Copies of the documents filed by Supernus with the SEC will be available free of charge on Supernus’ website at

www.supernus.com.

PARTICIPANTS IN THE SOLICITATION

Indivior and Supernus and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the

proposed transaction. Information about directors and executive officers of Indivior is available in the Indivior proxy statement for its 2026 Annual Meeting, which was filed with the SEC on March 27, 2026.

Information about directors and executive officers of Supernus is available in the Supernus proxy statement for its 2026 Annual Meeting, which was filed with the SEC on April 30, 2026. Other information

regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other

relevant materials filed with the SEC regarding the proposed transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before

making any voting or investment decisions. Investors may obtain free copies of these documents from Indivior and Supernus as indicated above.

Today's Presenters

Jack Khattar

President and Chief Executive Officer

Supernus Pharmaceuticals

Joe Ciaffoni

Chief Executive Officer

Indivior Pharmaceuticals

Tim Dec

Senior Vice President, Chief Financial Officer

Supernus Pharmaceuticals

Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Creates a CNS leader through the combination of two highly complementary businesses

Combines two differentiated commercial portfolios, creating a portfolio of 11 medicines

with key growth products currently expected to continue growing well into the 2030s

Establishes four key commercial therapeutic areas in addiction, ADHD, postpartum

depression, and Parkinson's disease, serving millions of patients

Accelerates profitability and cash flow generation with expected annual cost synergies of

at least $125 million

Preserves balance sheet strength and enhances flexibility to pursue future business

development and other growth opportunities

Creates a $2.2Bn(1) CNS

leader with a diversified

portfolio and significant

financial resources to

accelerate growth

opportunities

11 medicines

4 key therapeutic areas

$125m anticipated run rate synergies

(1) Pro-forma combined net revenues for the 12 months ended June 30, 2026.

Transaction

Summary

TRANSACTION STRUCTURE

• 100% tax-free stock-for-stock merger

• Supernus shareholders to receive 1.5401 Indivior shares

for each Supernus share

CASH DISTRIBUTION TO INDIVIOR

SHAREHOLDERS

• Prior to closing, Indivior will declare a dividend of $1B in

the aggregate to pre-closing stockholders

OWNERSHIP POST CLOSE

• 56.5% Indivior shareholders

• 43.5% Supernus shareholders

GOVERNANCE AND LEADERSHIP

• 4 Directors from Supernus / 4 Directors from Indivior,

including Tony Kingsley, Non-executive Board Chair

• President and Chief Executive Officer: Jack Khattar

• Expanded current Supernus executive team

NAME AND HEADQUARTERS

• Company name: Supernus, Inc.

• Headquarters: Rockville, Maryland

TIMING AND APPROVALS

• Targeted close Q4 2026

• Subject to approval of shareholders of both Supernus and

Indivior

• Subject to certain regulatory approvals and customary

closing conditions

(Epilepsy and Prophylaxis of

Migraine)

Combination Creates CNS Leader with a ~$2.2Bn⁽¹⁾ Diversified

Portfolio of Commercial Assets

G ADDICTION /

USE DISORDERS PSYCHIATRY NEUROLOGY

COMBINED COMPANY NET REVENUE

LTM as of 6/30/26

$2,162

million

INDIVIOR

Total Sublocade $956

Suboxone Film (US) $227

Ex-US Suboxone Tablets

and Film $119

Other $30

SUPERNUS

Qelbree $329

Other $233

Gocovri $152

Zurzuvae $116

Diversified portfolio of 11 commercial products with 5 key growth drivers

(1) $2,162m of pro forma combined net revenue for the twelve months ended 6/30/26. Note: Supernus Pharmaceuticals is jointly commercializing ZURZUVAE in the U.S. under a collaboration agreement with Biogen Inc.

(Opioid Use Disorder)

(ADHD)

(Postpartum Depression)

(Levodopa-Induced Dyskinesia)

(Hypomobility / “Off” Episodes in

Parkinson’s Disease)

(Cervical Dystonia)

(Partial-Onset Seizures)

Growth Products

(Not promoted in the U.S.) ("Off” Episodes in Parkinson’s

Disease)

(Hypomobility / “Off” Episodes in

Parkinson’s Disease)

Ideal Time to Build on Supernus and Indivior Strategic Progress

Supernus Indivior

STRATEGIC FOCUS

• Expanding portfolio through growth of current commercial portfolio,

business development, and advancement of mid- to late-stage

innovative CNS pipeline

• Successful track record of acquiring and integrating businesses

• Leadership in developing and commercializing treatments to help

people achieve long-term recovery from opioid use disorder (OUD)

• Implemented 3-phase Indivior Action Agenda to grow SUBLOCADE,

simplify the business, and strengthen financial position

PROGRESS

• Strengthened presence in neuropsychiatry with 2025 acquisition of

Sage Therapeutics

• Obtained FDA approval and launched ONAPGO for Parkinson’s

disease (PD)

• Generated significant free cash flow

• Accelerated SUBLOCADE growth through improved commercial

execution and DTC campaign

• Simplified business resulting in reduction of operating expenses

• Generated significant operating leverage

Combined organization is well-positioned to drive the next phase of growth and value creation

PORTFOLIO

• Commercial portfolio of 9 medicines across psychiatry and neurology

• Growth products include Qelbree®, ZURZUVAE®, ONAPGO® and

GOCOVRI®

• Innovative pipeline assets in ADHD, depression, epilepsy and other

CNS disorders

• Commercial portfolio of 2 medicines in OUD

• SUBLOCADE is the #1 prescribed, first-in-class, monthly long-acting

injectable (LAI) for the treatment of moderate to severe OUD

Supernus CNS Pipeline to Drive Potential Long-Term Growth

PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING

SPN-817 Epilepsy

SPN-820 Depression

SPN-443 ADHD

Discovery CNS

Wholly-owned CNS pipeline provides optionality beyond the commercial portfolio

Note: Bar extent reflects the most advanced stage of development for each program.

Pro Forma Key Financial Metrics

LTM as of 6/30/26⁽¹⁾ · $ in millions

$2,162m

Total net revenue

$888m

Adjusted EBITDA⁽²⁾

41%

Adjusted EBITDA margin⁽²⁾

<1x

Net leverage⁽⁴⁾

Supernus Indivior PRO FORMA

COMBINED COMPANY

Total Net Revenue $830 $1,332 $2,162

Adjusted EBITDA $150 $613 $888⁽²⁾

Adjusted EBITDA Margin 18% 46% 41%⁽²⁾

Net Debt ($372) $251 $878⁽3⁾

Net Leverage Ratio (2.47x) 0.41x 0.99x⁽⁴⁾

(1) Side-by-side combined financials are presented for illustrative purposes only and have not been adjusted for accounting differences or purchase accounting.

(2) Includes expected annual cost synergies of $125 million.

(3) Pro forma net debt reflects reported net debt as of 6/30/26, adjusted for the addition of $650 million of debt assumed to be drawn to fund the dividend and the dividend payment. Pro forma net debt does not reflect transaction costs, financing

fees, or costs to achieve synergies.

(4) Pro forma net debt (gross debt less cash and cash equivalents) divided by LTM Adjusted EBITDA (Adjusted Operating Earnings), including expected annual cost synergies of at least $125 million.

Value Creating

Transaction

Builds a diversified CNS

biopharmaceutical leader

with significant scale

Enhances and diversifies growth profile

Differentiated portfolio with key growth products expected to continue growing well into the 2030s

Four key commercial therapeutic areas

Increased scale and immediate significant cost synergies

Greater flexibility and capacity to pursue growth initiatives

Significant value creation for shareholders with upside from potential multiple expansion

Accelerated Profitability and Cash Flow Generation Drives

Greater Financial Flexibility

Drive growth in commercial portfolio

Invest behind SUBLOCADE, Qelbree, ZURZUVAE, ONAPGO and GOCOVRI

Advance development pipeline

Fund mid- to late-stage CNS programs through value-creating milestones

Pursue future business development

Expanded capacity for portfolio-expanding transactions

Q&A

GRAPHIC

Filename: tm2622009d4_ex99-1img0001.jpg · Sequence: 6

Binary file (112078 bytes)

Download tm2622009d4_ex99-1img0001.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img001.jpg · Sequence: 7

Binary file (359859 bytes)

Download tm2622009d4_ex99-1img001.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img002.jpg · Sequence: 8

Binary file (180831 bytes)

Download tm2622009d4_ex99-1img002.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img003.jpg · Sequence: 9

Binary file (57781 bytes)

Download tm2622009d4_ex99-1img003.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img004.jpg · Sequence: 10

Binary file (144776 bytes)

Download tm2622009d4_ex99-1img004.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img005.jpg · Sequence: 11

Binary file (142054 bytes)

Download tm2622009d4_ex99-1img005.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img006.jpg · Sequence: 12

Binary file (153508 bytes)

Download tm2622009d4_ex99-1img006.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img007.jpg · Sequence: 13

Binary file (163935 bytes)

Download tm2622009d4_ex99-1img007.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img008.jpg · Sequence: 14

Binary file (74150 bytes)

Download tm2622009d4_ex99-1img008.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img009.jpg · Sequence: 15

Binary file (100476 bytes)

Download tm2622009d4_ex99-1img009.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img010.jpg · Sequence: 16

Binary file (117003 bytes)

Download tm2622009d4_ex99-1img010.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img011.jpg · Sequence: 17

Binary file (80680 bytes)

Download tm2622009d4_ex99-1img011.jpg

GRAPHIC

Filename: tm2622009d4_ex99-1img012.jpg · Sequence: 18

Binary file (81257 bytes)

Download tm2622009d4_ex99-1img012.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 20

v3.26.1

Cover

Aug. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 03, 2026

Entity File Number

001-35518

Entity Registrant Name

Supernus

Pharmaceuticals, Inc.

Entity Central Index Key

0001356576

Entity Tax Identification Number

20-2590184

Entity Incorporation, State or Country Code

Entity Address, Address Line One

9715

Key West Ave

Entity Address, City or Town

Rockville

Entity Address, State or Province

Entity Address, Postal Zip Code

20850

City Area Code

301

Local Phone Number

838-2500

Written Communications

true

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.001 par value per share

Trading Symbol

SUPN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration